Compass Therapeutics (CMPX) Stock Forecast, Price Target & Predictions
CMPX Stock Forecast
Compass Therapeutics stock forecast is as follows: an average price target of $5.00 (represents a 264.96% upside from CMPX’s last price of $1.37) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
CMPX Price Target
The average price target for Compass Therapeutics (CMPX) is $5.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $5.00. This represents a potential 264.96% upside from CMPX's last price of $1.37.
CMPX Analyst Ratings
According to 2 Wall Street analysts, Compass Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CMPX stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 0 'Hold' (0.00%), 1 'Sell' (50.00%), and 0 'Strong Sell' (0.00%).
Compass Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 16, 2024 | Aydin Huseynov | Compass Point | $5.00 | $1.65 | 203.03% | 264.96% |
The latest Compass Therapeutics stock forecast, released on Sep 16, 2024 by Aydin Huseynov from Compass Point, set a price target of $5.00, which represents a 203.03% increase from the stock price at the time of the forecast ($1.65), and a 264.96% increase from CMPX last price ($1.37).
Compass Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $5.00 | $5.00 |
| Last Closing Price | $1.37 | $1.37 | $1.37 |
| Upside/Downside | -100.00% | 264.96% | 264.96% |
In the current month, the average price target of Compass Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Compass Therapeutics's last price of $1.37. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 13, 2024 | Jefferies | Buy | Buy | Hold |
| Apr 26, 2022 | Zacks Investment Research | - | Sell | Downgrade |
Compass Therapeutics's last stock rating was published by Jefferies on May 13, 2024. The company gave CMPX a "Buy" rating, the same as its previous rate.
Compass Therapeutics Financial Forecast
Compass Therapeutics Revenue Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - |
Compass Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. CMPX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Compass Therapeutics EBITDA Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - |
undefined analysts predict CMPX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Compass Therapeutics's previous annual EBITDA (undefined) of $NaN.
Compass Therapeutics Net Income Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - |
| Avg Forecast | $-12.75M | $-11.84M | $-11.84M | $-11.38M | $-13.47M | $-15.42M | $-13.17M | $-15.42M |
| High Forecast | $-12.75M | $-11.84M | $-11.84M | $-9.96M | $-9.43M | $-15.42M | $-13.17M | $-15.42M |
| Low Forecast | $-12.75M | $-11.84M | $-11.84M | $-11.38M | $-20.20M | $-15.42M | $-13.17M | $-15.42M |
| Surprise % | - | - | - | - | - | - | - | - |
Compass Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CMPX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Compass Therapeutics SG&A Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - |
Compass Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to CMPX last annual SG&A of $NaN (undefined).
Compass Therapeutics EPS Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.09 | $-0.09 | $-0.09 | $-0.08 | $-0.10 | $-0.11 | $-0.10 | $-0.11 |
| High Forecast | $-0.09 | $-0.09 | $-0.09 | $-0.07 | $-0.07 | $-0.11 | $-0.10 | $-0.11 |
| Low Forecast | $-0.09 | $-0.09 | $-0.09 | $-0.08 | $-0.15 | $-0.11 | $-0.10 | $-0.11 |
| Surprise % | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Compass Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CMPX previous annual EPS of $NaN (undefined).
Compass Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IVA | Inventiva | $2.74 | $36.00 | 1213.87% | Buy |
| PEPG | PepGen | $4.40 | $29.50 | 570.45% | Buy |
| GOSS | Gossamer Bio | $0.70 | $3.75 | 435.71% | Buy |
| AVTE | Aerovate Therapeutics | $2.66 | $13.00 | 388.72% | Hold |
| CMPX | Compass Therapeutics | $1.37 | $5.00 | 264.96% | Buy |
| VIGL | Vigil Neuroscience | $3.05 | $11.00 | 260.66% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| GPCR | Structure Therapeutics | $32.71 | $92.40 | 182.48% | Buy |
| LYRA | Lyra Therapeutics | $0.18 | $0.50 | 177.78% | Hold |
| PRTC | PureTech Health | $21.70 | $57.00 | 162.67% | Buy |
| ANAB | AnaptysBio | $20.31 | $52.00 | 156.03% | Buy |
| CGEM | Cullinan Oncology | $12.58 | $31.50 | 150.40% | Buy |
| REPL | Replimune Group | $11.23 | $24.20 | 115.49% | Buy |
| TYRA | Tyra Biosciences | $15.87 | $31.75 | 100.06% | Buy |
| KRON | Kronos Bio | $0.86 | $1.63 | 89.53% | Buy |
| KROS | Keros Therapeutics | $54.14 | $102.60 | 89.51% | Buy |
| NAMS | NewAmsterdam Pharma Company | $20.01 | $36.50 | 82.41% | Buy |
| IDYA | IDEAYA Biosciences | $25.54 | $46.58 | 82.38% | Buy |
| MLTX | MoonLake Immunotherapeutics | $49.82 | $79.33 | 59.23% | Buy |
| ELVN | Enliven Therapeutics | $25.43 | $39.50 | 55.33% | Buy |
| MGTX | MeiraGTx | $5.82 | $9.00 | 54.64% | Buy |